Tempus’ automated alerts boost patient outcomes in valvular heart disease
Tempus and Medtronic have uncovered the potential of artificial intelligence (AI)-driven electronic clinician notifications (ECNs) in improving outcomes and supporting…
News
Data shows 6.7% of global clinical trials impacted by Middle East disruption
Agenus enrols first patient in BATTMAN Phase III trial
Actinogen treats first patient in XanaMIA trial for Alzheimer’s
Oric to advance prostate cancer drug to Phase III trials
EMA backs virtual animal control as preclinical NAM amid animal testing phaseout
LabConnect unveils SampleGISTICS 2.0 for trial sample digitisation
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa
